Clinical and translational profiling of oncotherad (MRB-CFI-1) nanoimmunotherapy identifies HER-2/SERBP1–associated recurrence and HABP4/IFN-γ–associated disease control in pT1 non-muscle-invasive bladder cancer after BCG failure

Juliana Mattoso Gonçalves, Gabriela Cardoso de Arruda Camargo, Gabriela de Oliveira, Paulo Henrique Ferreira Caria, André da Silva Santos, José Ronaldo de Castro Roston, Thaís de Moraes Lacerda, Marcelo Bispo de Jesus, Leandro Luiz Lopes de Freitas, Martim Corrêa Bottene, Jean Felipe Prodocimo Lestingi, Jörg Kobarg, Nelson Durán, João Carlos Cardoso Alonso, Wagner José Fávaro

Open source

DOI: 10.1007/s00432-026-06581-y
Published: 2026-08-11
Container: Journal of Cancer Research and Clinical Oncology
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s00432-026-06581-y,
  title = {Clinical and translational profiling of oncotherad (MRB-CFI-1) nanoimmunotherapy identifies HER-2/SERBP1–associated recurrence and HABP4/IFN-γ–associated disease control in pT1 non-muscle-invasive bladder cancer after BCG failure},
  author = {Juliana Mattoso Gonçalves and Gabriela Cardoso de Arruda Camargo and Gabriela de Oliveira and Paulo Henrique Ferreira Caria and André da Silva Santos and José Ronaldo de Castro Roston and Thaís de Moraes Lacerda and Marcelo Bispo de Jesus and Leandro Luiz Lopes de Freitas and Martim Corrêa Bottene and Jean Felipe Prodocimo Lestingi and Jörg Kobarg and Nelson Durán and João Carlos Cardoso Alonso and Wagner José Fávaro},
  year = {2026},
  journal = {Journal of Cancer Research and Clinical Oncology},
  doi = {10.1007/s00432-026-06581-y},
  url = {https://doi.org/10.1007/s00432-026-06581-y}
}

RIS

TY  - JOUR
TI  - Clinical and translational profiling of oncotherad (MRB-CFI-1) nanoimmunotherapy identifies HER-2/SERBP1–associated recurrence and HABP4/IFN-γ–associated disease control in pT1 non-muscle-invasive bladder cancer after BCG failure
AU  - Juliana Mattoso Gonçalves
AU  - Gabriela Cardoso de Arruda Camargo
AU  - Gabriela de Oliveira
AU  - Paulo Henrique Ferreira Caria
AU  - André da Silva Santos
AU  - José Ronaldo de Castro Roston
AU  - Thaís de Moraes Lacerda
AU  - Marcelo Bispo de Jesus
AU  - Leandro Luiz Lopes de Freitas
AU  - Martim Corrêa Bottene
AU  - Jean Felipe Prodocimo Lestingi
AU  - Jörg Kobarg
AU  - Nelson Durán
AU  - João Carlos Cardoso Alonso
AU  - Wagner José Fávaro
PY  - 2026
JO  - Journal of Cancer Research and Clinical Oncology
DO  - 10.1007/s00432-026-06581-y
UR  - https://doi.org/10.1007/s00432-026-06581-y
ER  -

APA

Gonçalves, J. M., Camargo, G. C. D. A., Oliveira, G. D., Caria, P. H. F., Santos, A. D. S., Roston, J. R. D. C., Lacerda, T. D. M., Jesus, M. B. D., Freitas, L. L. L. D., Bottene, M. C., Lestingi, J. F. P., Kobarg, J., Durán, N., Alonso, J. C. C., & Fávaro, W. J. (2026). Clinical and translational profiling of oncotherad (MRB-CFI-1) nanoimmunotherapy identifies HER-2/SERBP1–associated recurrence and HABP4/IFN-γ–associated disease control in pT1 non-muscle-invasive bladder cancer after BCG failure. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-026-06581-y

Source records

crossref · retrieved 2026-11-10T12:24:47.255Z